What is Geno?
Geno is a pioneer in the field of synthetic biology, dedicated to the development of clean manufacturing processes that produce essential ingredients for everyday products. By utilizing plants and waste streams as feedstocks, the company offers a viable, sustainable alternative to conventional materials derived from fossil fuels or environmentally taxing sources like palm oil. Geno's market position is defined by its successful commercialization of high-performance ingredients for plastics, spandex, and personal care products, with an active pipeline expanding into nylon and household cleaning agents. The company serves as a critical link in the global transition toward a circular economy, providing enterprise-level solutions that do not compromise on quality or performance.
How much funding has Geno raised?
Geno has raised a total of $333.1M across 7 funding rounds:
Series A
$4M
Series B
$20M
Series C
$15M
Unspecified
$45M
Unspecified
$41.1M
Unspecified
$90M
Unspecified
$118M
Series A (2002): $4M, investors not publicly disclosed
Series B (2007): $20M led by Draper Fisher Jurvetson (DFJ) and Mohr Davidow Ventures
Series C (2010): $15M supported by Mohr Davidow Ventures, Draper Fisher Jurvetson, TPG Biotechnology Partners, and Alloy Ventures
Unspecified (2011): $45M, investors not publicly disclosed
Unspecified (2012): $41.1M, investors not publicly disclosed
Unspecified (2018): $90M with participation from Ginkgo Bioworks, Casdin Capital, and Viking Global Investors
Unspecified (2021): $118M led by Novo Holdings
Key Investors in Geno
Draper Fisher Jurvetson
A prominent venture capital firm with a global reach, DFJ focuses on identifying and backing extraordinary entrepreneurs who are poised to catalyze significant industry change.
Casdin Capital
An investment firm that brings deep expertise and a long-term perspective to the financing of next-generation life science and molecular information innovation.
Novo Holdings
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation within the life sciences sector.
What's next for Geno?
With the support of its latest capital injection, Geno is positioned to accelerate the deployment of its synthetic biology platform across new industrial verticals. The strategic focus remains on scaling production capabilities to meet the rising demand for sustainable materials among global consumer brands. As the company matures, it is expected to deepen its integration into the supply chains of major manufacturers, further validating the economic and environmental viability of its bio-based ingredients. Future growth will likely be driven by continued investment in R&D and the expansion of its commercial footprint, ensuring that Geno remains at the forefront of the clean manufacturing revolution.
See full Geno company page
